An isolated peptide of (a) or (b) is disclosed. The isolated peptide a) consists of less than 15 amino acids in length, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 5, 31 and 32 as defined in the complete specification. The isolated peptide c) of less than 15 amino acids in length, comprising an amino acid sequence in which one or two amino acid(s) are substituted, deleted, inserted or added to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 5, 31 and 32 as defined in the complete specification to yield a modified peptide that retains the ability to bind to a human leukocyte antigen (HLA), and that retains cytotoxic T lymphocyte (CTL) inducibility, and the isolated peptide does not consist of a peptide having the amino acid sequence LYGRALRVL. An isolated polynucleotide encoding the above described peptide is also disclosed. An isolated antigen-presenting cell that presents on its surface a complex of an HLA antigen and the above described peptide is disclosed. An isolated cytotoxic T lymphocyte that targets the above described peptides is disclosed. A pharmaceutical composition comprises the above described peptide, polynucleotide, cytotoxic T lymphocyte or antigen-presenting cell for inducing an immune response against cancer in a subject, inducing cytotoxic T lymphocyte, or for treatment of an existing cancer, prophylaxis of a cancer and/or prevention of a postoperative recurrence of a cancer.
